MAPT and Alzheimer disease: A recent clinical study in AD patients was reported by Carlomagno et al., who developed an innovative SERS-based biosensor using 35 nm AgNPs to analyze human serum from AD patients well-characterized from an A/T/N (A = amyloid, T = tau; N = neurodegeneration) perspective, versus healthy subjects.